Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prilosec OTC impacting Protonix?

This article was originally published in The Tan Sheet

Executive Summary

Wyeth reiterates Procter & Gamble's recent launch of Prilosec OTC (omeprazole) will not impact sales of its Rx GERD treatment Protonix (pantoprazole sodium) (1"The Tan Sheet" July 28, 2003, p. 11). During Bear Stearns Healthcare Conference in New York City Sept. 9, Wyeth North America President Joseph Mahady notes "the change in market status from a single omeprazole generic to now having multiple generics...will more than likely have the most significant change on the market. In our opinion that will be more critical to the performance of Protonix in the future than will be the availability of an OTC version of Prilosec"...

You may also be interested in...



Alavert Sales Up 48% As Wyeth Stands Strong In Crowded Loratadine Market

Wyeth is confident that its Alavert loratadine product will weather the launch of several private label and generic rivals and build on the brand's strong second quarter sales performance

UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another

Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.

EU ‘Structured Dialog’ Offers Opportunity To Secure Supply

A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.

Topics

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel